ARCHIVES

Long-term Follow-up Shows ADH and ALH Tissue Abnormalities Can Carry Similar Risk

This article is from The Cancer Letter archive.

Vol. 37 No. 1 | January 31, 2014

Download PDF Visit The Full Archive

Related Articles

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

October 29, 2004

Three-Quarters of P01 $$ Goes To Translational Grants, NCI Finds

October 2, 1992

CDC Offers Funds For 5-A-Day Program; CDC PA Available

May 14, 1999

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

December 3, 2010

DCT Adopts New Unsolicited Contract Review Procedures

May 21, 1976

New Jersey Center Takes Slice of DOE Budget for Cancer

January 8, 1988